Immune-response profiles induced by human immunodeficiency virus type 1 vaccine: DNA, protein or mixed-modality immunization: Increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination

Journal of General Virology

Volumn 89, Issue 2, 2008, Pages 540-553

  Koopman, Gerrit ^a   Mortier, Daniella ^a   Hofman, Sam ^a   Mathy, Nathalie ^b   Koutsoukas, Marguerite ^b   Ertl, Peter ^c   Overend, Phil ^c   vanWely, Cathy ^c   Thomsen, Lindy L ^c   Wahren, Britta ^d   Voss, Gerald ^b   Heeney, Jonathan L ^a,e  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c GLAXOSMITHKLINE   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIBODY; ANTIGEN; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; PLASMID DNA; RECOMBINANT PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; TH1 CELL; TH2 CELL; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; ANIMAL; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; MACACA; METABOLISM; PHYSIOLOGY; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, VIRAL; GENE PRODUCTS, ENV; GENE PRODUCTS, TAT; HIV; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNIZATION; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA; VACCINES, SUBUNIT; VIREMIA; VIRUS REPLICATION;

EID: 41649098046     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.83384-0     Document Type: Article

References (58)

1. Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G. & other authors (2001). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74.
2. Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G. & other authors (2002). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Vaccine 20, 1949-1955.
3. Barouch, D. H., Craiu, A., Kuroda, M. J., Schmitz, J. E., Zheng, X. X., Santra, S., Frost, J. D., Krivulka, G. R., Lifton, M. A. & other authors (2000). Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A 97, 4192-4197.
4. Barouch, D. H., Craiu, A., Santra, S., Egan, M. A., Schmitz, J. E., Kuroda, M. J., Fu, T. M., Nam, J. H., Wyatt, L. S. & other authors (2001). Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J Virol 75, 2462-2467.
5. Berman, P. W., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Wurm, F. M., Hershberg, R. D., Cobb, E. K. & Eichberg, J. W. (1990). Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625.
6. Eichberg, J. W. (1990). Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622-625.
7. Brave, A., Ljungberg, K., Wahren, B. & Liu, M. A. (2007). Vaccine delivery methods using viral vectors. Mol Pharm 4, 18-32.
8. Bruck, C., Thiriart, C., Fabry, L., Francotte, M., Pala, P., Van Opstal, O., Culp, J., Rosenberg, M., De Wilde, M. & other authors (1994). HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees. Vaccine 12, 1141-1148.
9. Cafaro, A., Titti, F., Fracasso, C., Maggiorella, M. T., Baroncelli, S., Caputo, A., Goletti, D., Borsetti, A., Pace, M. & other authors (2001). Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19, 2862-2877.
10. Calarota, S., Bratt, G., Nordlund, S., Hinkula, J., Leandersson, A. C., Sandstrom, E. & Wahren, B. (1998). Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351, 1320-1325.
11. Casimiro, D. R., Wang, F., Schleif, W. A., Liang, X., Zhang, Z. O., Tobery, T. W., Davies, M. E., McDermott, A. B., O'Connor, D. H. & other authors (2005). Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79, 15547-15555.
12. Cristillo, A. D., Wang, S., Caskey, M. S., Unangst, T., Hocker, L., He, L., Hudacik, L., Whitney, S., Keen, T. & other authors (2006). Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 346, 151-168.
13. Dale, C. J., De Rose, R., Stratov, I., Chea, S., Montefiori, D. C., Thomson, S., Ramshaw, I. A., Coupar, B. E., Boyle, D. B. & other authors (2004). Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J Virol 78, 13819-13828.
14. Desrosiers, R. C. (2004). Prospects for an AIDS vaccine. Nat Med 10, 221-223.
15. Doria-Rose, N. A., Ohlen, C., Polacino, P., Pierce, C. C., Hensel, M. T., Kuller, L., Mulvania, T., Anderson, D., Greenberg, P. D. & other authors (2003). Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol 77, 11563-11577.
16. Earl, P. L., Sugiura, W., Montefiori, D. C., Broder, C. C., Lee, S. A., Wild, C., Lifson, J. & Moss, B. (2001). Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 75, 645-653.
17. Earl, P. L., Wyatt, L. S., Montefiori, D. C., Bilska, M., Woodward, R., Markham, P. D., Malley, J. D., Vogel, T. U., Allen, T. M. & other authors (2002). Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 294, 270-281.
18. Egan, M. A., Chong, S. Y., Hagen, M., Megati, S., Schadeck, E. B., Piacente, P., Ma, B. J., Montefiori, D. C., Haynes, B. F. & other authors (2004). A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 22, 3774-3788.
19. Estcourt, M. J., McMichael, A. J. & Hanke, T. (2004). DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 199, 144-155.
20. Girard, M., Kieny, M. P., Pinter, A., Barre-Sinoussi, F., Nara, P., Kolbe, H., Kusumi, K., Chaput, A., Reinhart, T. & other authors (1991). Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sci U S A 88, 542-546.
21. Heeney, J. L. (2004). Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses. Expert Rev Vaccines 3, S53-S64.
22. Heaney, J. L. (2006). Preclinical primate studies of HIV-1-envelope-based vaccines: towards human clinical trials. Curr Opin HIV AIDS 1, 336-343.
23. Heeney, J. L. & Plotkin, S. A. (2006). Immunological correlates of protection from HIV infection and disease. Nat Immunol 7, 1281-1284.
24. + T cell responses. J Immunol 169, 4778-4787.
25. Hel, Z., Tsai, W. P., Tryniszewska, E., Nacsa, J., Markham, P. D., Lewis, M. G., Pavlakis, G. N., Felber, B. K., Tertaglia, J. & Franchini, G. (2006). Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J Immunol 176, 85-96.
26. Hu, S. L., Abrams, K., Barber, G. N., Moran, P., Zarling, J. M., Langlois, A. J., Kuller, L., Morton, W. R. & Benveniste, R. E. (1992). Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255, 456-459.
27. + T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189, 991-998.
28. + T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens. J Gen Virol 85, 2915-2924.
29. Letvin, N. L., Montefiori, D. C., Yasutomi, Y., Perry, H. C., Davies, M. E., Lekutis, C., Alroy, M., Freed, D. C., Lord, C. I. & other authors (1997). Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 94, 9378-9383.
30. Letvin, N. L., Barouch, D. H. & Montefiori, D. C. (2002). Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 20, 73-99.
31. Letvin, N. L., Huang, Y., Chakrabarti, B. K., Xu, L., Seaman, M. S., Beaudry, K., Korloth-Schmitz, B., Yu, F., Rohne, D. & other authors (2004). Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 78, 7490-7497.
32. Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P. & other authors (2005). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79, 10108-10125.
33. Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S. & other authors (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6, 207-210.
34. Mascola, J. R., Sambor, A., Beaudry, K., Santra, S., Welcher, B., Louder, M. K., Vancott T. C., Huang, Y., Chakrabarti, B. K. & other authors (2005). Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 79, 771-779.
35. Messer, R. J., Dittmer, U., Peterson, K. E. & Hasenkrug, K. J. (2004). Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection. Proc Natl Acad Sci U S A 101, 12260-12265.
36. Monteflori, D. C., Pantaleo, G., Fink, L. M., Zhou, J. T., Zhou, J. Y., Bilska, M., Miralles, G. D. & Fauci, A. S. (1996). Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 173, 60-67.
37. Mooij, P., van der Kolk, M., Bogers, W. M., ten Haaft, P. J., Van Der Meide, P., Almond, N., Stott, J., Deschamps, M. Labbe, D. & other authors (1998). A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection. AIDS 12, F15-F22.
38. Mooij, P., Bogers, W. M., Oostermeijer, H., Koomstra, W., Ten Haaft, P. J., Verstrepen, B. E., Van Der Auwera, G. & Heeney, J. L. (2000). Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J Virol 74, 4017-4027.
39. Mooij, P., Nieuwenhuls, I. G., Knoop, C. J., Doms, R. W., Bogers, W. M., Ten Haaft, P. J., Niphuls, H., Koornstra, W., Bieler, K. & other authors (2004). Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J Virol 78, 3333-3342.
40. Otten, G. R., Schaefer, M., Doe, B., Liu, H., Srivastava, I., Megede, J., Kazzaz, J., Lian, Y., Singh, M. & other authors (2005). Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 79, 8189-8200.
41. Pal, R., Wang, S., Kalyanaraman, V. S., Nair, B. C., Whitney, S., Keen, T., Hocker, L., Hudacik, L., Rose, N. & other authors (2005). Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate. J Med Primatol 34, 226-236.
42. Pal, R., Kalyanaraman, V. S., Nair, B. C., Whitney, S., Keen, T., Hocker, L., Hudacik, L., Rose, N., Mboudjeka, I. & other authors (2006). Immunization of rhesus macaques with a polyvalent DNA prime/ protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348, 341-353.
43. Pantaleo, G. & Fauci, A. S. (1996). Immunopathogenesis of HIV infection. Annu Rev Microbiol 50, 825-854.
44. mac251 challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78, 2212-2221.
45. Pauza, C. D., Trivedi, P., Wallace, M., Ruckwardt, T. J., Le Buanec, H., Lu, W., Bizzini, B., Bumy, A., Zagury, D. & Gallo, R. C. (2000). Vaccination with tat toxoid attenuates disease in simian/ HIV-challenged macaques. Proc Natl Acad Sci U S A 97, 3515-3519.
46. Ranjbar, S., Jones, S., Stott, E. J. & Almond, N. (1997). The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV type 1 isolates. AIDS Res Hum Retroviruses 13, 797-800.
47. Reimann, K. A., Li, J. T., Veazey, R., Halloran, M., Park, I. W., Karlsson, G. B., Sodraski, J. & Letvin, N. L. (1996). A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 70, 6922-6928.
48. Robinson, H. L. (1999). DNA vaccines: basic mechanism and immune responses. Int J Mol Med 4, 549-555 (Review)
49. Robinson, H. L., Montefiori, D. C., Johnson, R. P., Manson, K. H., Kalish, M. L., Lifson, J. D., Rizvi, T. A., Lu, S., Hu, S. L. & other authors (1999). Neutralizing antibody-independent containment of immuno-deficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5, 526-534.
50. Rollman, E., Mathy, N., Brave, A., Boberg, A., Kjerrstrom, A., van Wely, C., Engstrom, G., Johansson, S., Aperia K. & other authors (2007). Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/ murine leukemia virus pseudotype challenge model. Vaccine 25, 2145-2154.
51. Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., Racz, P., Tenner-Racz, K., Dalesandro, M. & other authors (1999). Control of viremia in simian immunodeficiency virus infection by CD8 + lymphocytes. Science 283, 857-860.
52. Seth, A., Ourmanov, I., Schmitz, J. E., Kuroda, M. J., Lifton, M. A., Nickerson, C. E., Wyatt, L., Carroll, M., Moss, B. & other authors (2000). Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 74, 2502-2509.
53. Shiver, J. W., Fu, T. M., Chen, L., Casimiro, D. R., Davies, M. E., Evans, R. K., Zhang, Z. O., Simon, A. J., Trigona, W. L. & other authors (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335.
54. Stittelaar, K. J., Gruters, R. A., Schutten, M., van Baalen, C. A., van Amerongen, G., Cranage, M., Liljestrom, P., Sutter, G. & Osterhaus, A. D. (2002). Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 20, 2921-2927.
55. Ten Haaft, P., Verstrepen, B., Uberla, K., Rosenwirth, B. & Heaney, J. (1998). A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol 72, 10281-10285.
56. Verschoor, E. J., Mooij, P., Oostermeijer, H., van der Kolk, M., ten Haaft, P., Verstrepen, B., Sun, Y., Morein, B., Akerblom, L. & other authors (1999). Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. J Virol 73, 3292-3300.
57. Voss, G., Manson, K., Montefiori, D., Watkins, D. I., Heeney, J., Wyand, M., Cohen, J. & Bruck, C. (2003). Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol 77, 1049-1058.
58. Wilson, N. A., Reed, J., Napoe, G. S., Piaskowski, S., Szymanski, A., Furlott J., Gonzalez, E. J., Yant, L. J., Maness, N. J. & other authors (2006). Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 80, 5875-5885.